Methods for treating hematological disorders with VWF-targeting monospecific antibodies - Patents.com

Abstract

Provided herein are von Willebrand factor-binding antibodies directed to epitopes located in the cysteine ​​knot (CK) domain, which are useful in methods of treatment, such as methods of treating one or more blood disorders characterized by excessive bleeding.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 268,040, filed February 15, 2022, and U.S. Provisional Patent Application No. 63 / 269,000, filed March 8, 2022, the entire contents of which are incorporated herein by reference.

[0002] Sequence Listing This application has been submitted electronically in XML format and is accompanied by a Sequence Listing, which is incorporated herein by reference in its entirety. A copy of this XML was created on February 7, 2023, is named "HMT_002WO_Sequence Listing.xml", and is 457,851 bytes in size. Summary of the Invention

[0003] In certain embodiments, disclosed herein are compositions and methods for treating hematological disorders using monospecific antibodies targeted against von Willebrand factor (VWF).

[0004] In certain embodiments, disclosed herein are monospecific antibodies comprising an antigen-binding site that specifically binds to an epitope of von Willebrand factor (VWF) protein located in a cysteine ​​knot (CK) domain and a fragment crystallizable (Fc) region, wherein binding of the monospecific antibody disclosed herein to VWF protein results in accumulation of VWF protein in plasma compared to the plasma level of VWF protein in the absence of the monospecific antibody. In some embodiments, the antibodies disclosed herein are monovalent antibodies. In some embodiments, the Fc region is a wild-type Fc region. In some embodiments, the Fc region is a modified Fc region. In some embodiments, the modified Fc region comprises an R435H mutation, an N434A mutation, a T252L / T253S / T254F mutation, an E294delta / T307P / N434Y mutation, a T256N / A378V / S383N / N434Y mutation, an E294delta mutation, an M252Y / S254T / T256E mutation, an M428L / N434S mutation, a T307A / E380A / N434A mutation, an T250Q / M4 28L mutation, T250Q / M428F mutation, T250E / M428F mutation, T250E / M428L mutation, T256D / Q311V / A378V mutation, T256D / H286D / T307R / Q311V / A378V mutation, H285N / T307Q / N315D mutation, T307Q / Q311V / A378V mutation, H285D / T307Q / A378V mutation, L234F / L235E / P33 1S mutation, L234F / L235Q / K322Q mutation, L234F / L235Q / P331G mutation, L234F / L235A / K322Q mutation, S228P / F234A / L235A / G237A / P238S mutation, L234A / L235E / G237A / A330S / P331S mutation, F243A / V264A mutation, S228P / L235E / P329G mutation, M252Y / M428L mutations, D259I / V308F mutation, T307Q / N434S mutation, M428L / V308F mutation, Q311V / N434S mutation, H433K / N434F mutation, E258F / V427T mutation, K288E / H435K mutation, F234A / L235A mutation, F234A / L235A / S228P mutation, L234A / L235A / P329G mutation, F234A / L235A / P329G mutation,P329G mutation, F234 mutation, S228P mutation, delta-K447 mutation, L235A mutation, L235E mutation, V308P mutation, V308W mutation, V308Y mutation, V308F mutation, N434S mutation, T307 mutation, Q312A mutation, K322A mutation, P329A mutation, P331A mutation, P238A mutation, D265A mutation, D269A mutation, D270A mutation, N297A mutation, A32 The gene includes one or more mutations selected from the group consisting of a 7Q mutation, a P329A mutation, a S239A mutation, an E294A mutation, a Q295A mutation, a V303A mutation, an A330R mutation, a T299A mutation, a F234A mutation, a T366W mutation, a T366S mutation, a L368A mutation, a Y407V mutation, a F405L mutation, a K409R mutation, a F405L / R409K mutation, and any combination thereof. In some embodiments, the Fc region comprises an N-terminal truncation (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 20, 21, 2 In some embodiments, the antibody comprises a truncation by 2, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more N-terminal residues). In some embodiments, the antibody is a human IgG4 antibody comprising a first heavy chain and a second heavy chain. In some embodiments, the first heavy chain comprises S228P / T366W / F234A / L235A / delta-K447 mutations and the second heavy chain comprises S228P / T366S / L368A / Y407V / F234A / L235A / delta-K447 mutations. In some embodiments, the first heavy chain comprises S228P / T366W / delta-K447 mutations and the second heavy chain comprises S228P / T366S / L368A / Y407V / delta-K447 mutations. In some embodiments, the first heavy chain and the second heavy chain further comprise M252Y / S254T / T256E mutations. In some embodiments, the antibody comprises:and a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 16. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 16. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 16. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 16.The antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 15, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 12, and a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 15. H3, and a variable heavy chain (VH) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 16, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 18.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 453, and a variable light chain (VL) region at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 473. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 463; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 463. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 23. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 23. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 23.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 23. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 22, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 25.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 19, and a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 22. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 23 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 25.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 454, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 474. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 464; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 464. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO:26, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO:30. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 30. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 30.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 30. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 30. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 29, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 32.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 26, and a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 29. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 30 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 32, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 32. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 37.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 36, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of the DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 39.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 33, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 36. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 37 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 39, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 39.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 455, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 475. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 465; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 465. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 44. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 44. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 44.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 44. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 44. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 43, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 45, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GSS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 46.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 40, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 43. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 44, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 45, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: GSS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 46.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 456, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 476. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 466; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 466. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 51. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 51. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 51.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 51. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 48, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 49, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 50, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 52, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of the DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 53.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 47, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 48, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 49, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 50. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:51 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:52, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:53. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 58. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 58. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 58.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 58. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 58. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 57, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 59, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 60.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 54, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 57. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:58 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:59, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:60.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:457, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:477. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 467; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 467. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 65. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 65. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 65.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 65. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 67.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 61, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:65 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:67. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 72. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 72. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 72.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 72. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 72. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 71, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 74.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 68, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 71. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:72 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:73, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:74. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 79. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 79. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 79.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 79. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 79. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 78, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 80, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 81.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 75, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 78. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:79, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:80, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:81. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 86.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:86. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 83, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 85, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 87, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of the DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 88.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 82, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 83, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 85. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 86 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 87, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 88. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO:93. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 93. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 93.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 93. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:93. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 92, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 94, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 95.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 89, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 92. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:93, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:94, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:95.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:458, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:478. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 468; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 468. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 100. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 100. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 100.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 100. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 99, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 102.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 96, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 99. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 100 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 107.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 107. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 106, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 109.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 103, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 106. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 107 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 109. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 114. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 114. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 114.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 114. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 113, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 116.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 110, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 113. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 114, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 116.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 459, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 479. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 469; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 469. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 121. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 121. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 121.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 121. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 121. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 120, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 123.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 117, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 120. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 121 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 123. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 128. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 128. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 128.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 128. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 128. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 127, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 130.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 124, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 127. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 128 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 130. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 135. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 135. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 135.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 135. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 135. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 134, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 137.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 131, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 134. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 135 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 137. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 142. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 142. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 142.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 142. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 142. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 141, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 144.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 138, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 141. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 142, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 149. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 149. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 149.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 149. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 149. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 148, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 151.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 145, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 148. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 149 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 151. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 156. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 156. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 156.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 156. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 156. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 155, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 158.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 152, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 155. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 156 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 158. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 163. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 163. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 163.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 163. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 163. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 162, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 165.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 159, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 162. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 163 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 165. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 170. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 170. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 170.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 170. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 170. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 169, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 172.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 166, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 169. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 170, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 172. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 177. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 177. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 177.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 177. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 177. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 176, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 178, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 179.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 173, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 176. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 177 and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 178, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 179. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 184. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 184. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 184.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 184. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 184. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 183, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DVS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 186.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 180, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 183. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 184 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DVS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 186. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 191. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 191. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 191.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 191. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 191. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 190, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of the DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 193.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 187, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 190. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 86 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 191%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 193. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 198. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 198. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 198.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 198. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 198. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 197, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 200.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 194, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 197. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 198 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 200. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 205. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 205. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 205.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 205. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 205. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 204, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 206, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GVD, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 207.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 201, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 204. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 205, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 206, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GVD, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 207. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 212. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 212. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 212.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 212. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 212. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 211, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 213, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 214.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 208, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 211. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 212, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 213, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 214. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 219. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 219. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 219.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 219. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 219. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 218, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 221.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 215, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 218. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 219, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 221. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 226. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 226. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 226.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 226. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 226. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 225, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 227, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 228.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 222, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 225. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:226 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:227, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:228. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 233. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 233. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 233.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 233. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 233. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 232, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 234, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 235.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 229, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 232. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:233 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:234, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:235. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 240. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 240. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 240.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 240. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 240. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 239, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 242.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 236, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 239. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 240, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 242. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 247. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 247. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 247.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 247. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 247. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 246, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 249.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 243, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 246. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 247, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 249.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 460, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 480. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 470; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 470. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 254. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 254. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 254.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 254. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 254. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 253, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 256.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 250, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 253. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 254, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 255, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 256. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 261. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 261. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 261.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 261. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 261. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 260, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 263.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 257, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 260. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 261, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 263. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 268. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 268. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 268.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 268. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 268. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 267, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 269, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 270.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 264, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 267. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:268 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:269, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:270. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 275. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 275. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 275.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 275. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 275. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 274, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 277.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 271, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 274. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 275, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 277. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 282. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 282. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 282.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 282. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 282. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 281, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 284.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 278, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 281. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 282, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 284. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 289. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 289. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 289.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 289. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 289. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 288, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 291.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 285, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 288. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 289, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 291. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 296. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 296. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 296.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 296. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 296. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 295, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 297, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 298.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 292, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 295. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:296 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:297, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:298. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 303. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 303. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 303.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 303. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 303. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 302, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 305.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 299, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 302. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 303 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 305. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 310. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 310. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 310.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 310. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 310. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 309, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 312.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 306, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 309. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 310 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 312.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 461, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 481. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 471; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 471. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 317. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 317. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 317.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 317. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 317. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 316, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 319.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 313, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 316. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 317, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 318, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 319. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 324. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 324. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 324.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 324. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 324. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 323, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 326.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 320, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 323. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 324, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 326. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 331. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 331. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 331.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 331. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 331. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 330, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 333.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 327, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 330. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 331 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 333. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 338. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 338. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 338.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 338. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 338. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 337, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 340.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 334, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 337. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 338, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 340. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 345. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 345. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 345.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 345. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 344, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 347.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 341, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 344. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 345, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 347. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 352. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 352. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 352.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 352. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 352. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 351, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTA, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 354.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 348, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 351. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 352 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 354. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 359. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 359. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 359.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 359. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 359. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 358, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 361.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 355, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 358. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 359 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 361. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 366. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 366. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 366.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 366. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 366. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 365, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 368.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 362, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 365. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 366, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 368. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 373. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 373. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 373.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 373. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 373. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 372, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 375.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 369, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 372. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 373, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 375. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 380. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 380. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 380.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 380. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 380. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 379, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 382.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 376, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 379. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 380 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 382. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 387. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 387. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 387.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 387. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 387. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 386, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 389.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 383, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 386. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 387, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 389. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 394. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 394. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 394.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 394. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 394. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 393, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 396.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 390, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 393. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 394 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 396.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 462, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 482. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 472; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 472. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 401. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 401. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 401.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 401. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 401. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 400, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 403.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 397, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 400. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 401, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 403. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 408. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 408. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 408.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 408. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 408. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 407, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 409, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 410.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 404, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 407. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:408 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:409, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:410. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 415. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 415. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 415.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 415. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 415. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 414, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 416, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 417.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 411, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 414. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 415, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 416, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAF, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 417. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 422. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 422. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 422.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 422. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 422. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 421, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 424.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 418, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 421. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 422, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 424. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 429. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 429. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 429.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 429. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 429. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 428, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 431.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 425, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 428. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 429, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 431. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 436. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 436. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 436.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 436. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 436. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 435, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 438.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 432, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 435. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 436, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 438. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 443. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 443. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 443.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 443. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 443. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 442, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 445.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 439, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 442. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 443 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 445. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 450. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 450. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 450.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 450. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 450. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 449, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 452.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 446, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 449. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:450 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:451, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:452. In some embodiments, the antibody binds to one or more amino acid residues in the VWF CK domain selected from D2726, R2730, K2735, E2744, D2746, K2757, D2763, and T2789. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: D2726, R2730, D2746, and K2757. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: R2730, K2735, E2744, and D2746. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: K2735, D2746, and K2757. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: R2730, D2746, and K2757.In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: K2735, E2744, D2746, and D2763. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: R2730, K2735, E2744, D2746, K2757, and D2763. In some embodiments, the antibody binds to at least amino acid residue K2735 in the VWF CK domain. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: D2726, K2735, and K2757. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: K2735 and D2763. In some embodiments, the modified Fc region increases the plasma half-life of the antibody compared to the plasma half-life of an antibody lacking the Fc region modification. In some embodiments, the modified Fc region increases the plasma half-life of an antibody disclosed herein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or more than 20-fold compared to the plasma half-life of an antibody lacking the Fc region modification. In some embodiments, the modified Fc region increases the plasma half-life of an antibody disclosed herein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 75 ...100%, 150%, 100%, 150%, 100%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 0%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000%, or more. In some embodiments, the modified Fc region reduces one or more effector functions of an antibody disclosed herein compared to an effector function of an antibody lacking the Fc region modification.In some embodiments, the one or more effector functions are selected from the group consisting of antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), opsonization, phagocytosis, transcytosis, neutralization of infectivity, inflammation, mucosal immunity, and neonatal immunity. In some embodiments, the modified Fc region reduces one or more effector functions of an antibody disclosed herein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to one or more effector functions of an antibody lacking the Fc region modification. In some embodiments, the modified Fc region reduces one or more effector functions of an antibody disclosed herein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to one or more effector functions of an antibody lacking the Fc region modification. In some embodiments, binding of an antibody disclosed herein to a VWF protein does not alter the function of the VWF protein. In some embodiments, binding of an antibody disclosed herein to VWF (e.g., the VWF CK domain) does not inhibit the binding of the VWF protein to one or more binding partners. In some embodiments, the one or more binding partners are selected from the group consisting of Factor VIII (FVIII), collagen, glycoprotein Ib (gp1b), glycoprotein IIb / IIIa (gpIIb / IIIa), and ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13 (ADAMTS13). In some embodiments, the binding of the antibodies disclosed herein does not inhibit VWF protein from binding to platelet cells. In some embodiments, the accumulation of VWF protein in plasma results in a plasma level of VWF protein that is at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater than the plasma level of VWF protein in the absence of the antibody.In some embodiments, the accumulation of VWF protein in plasma is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 1000%, 1100%, 1200%, 1300%, 1400%, 1500%, 1600%, 1700%, 1800%, 1900%, 2100%, 2200%, 2300%, 2400%, 2500%, 3000%, 3500%, 4000%, 4500%, 5000%, 5500%, 6000%, 6500%, 7000%, 7500%, 8000%, 9000%, 10000%, 11000%, 12000%, 13000%, 14000%, 15000%, 16000%, 17000%, 18000%, 19000%, 21000%, 22000%, 23000%, 24000%, 25000%, 26000%, 27000%, 28000%, 29000%, 30000%, 31000%, 32000%, 33000%, 34000%, 35000%, 36000%, 37000%, 38000%, 39000%, 41000 In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the VWF protein compared to the plasma half-life of the VWF protein in the absence of the antibody. In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the VWF protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to the plasma half-life of the VWF protein in the absence of the antibody. In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the VWF protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, compared to the plasma half-life of the VWF protein in the absence of the antibody. %, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, or 10,000% increase. In some embodiments, the binding of an antibody disclosed herein to a VWF protein in plasma results in the accumulation of a VWF protein in plasma compared to the plasma level of the FVIII protein in the absence of the antibody. In some embodiments, the accumulation of the FVIII protein in plasma results in a plasma level of the FVIII protein that is at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater than the plasma level of the FVIII protein in the absence of the antibody. In some embodiments, the accumulation of FVIII protein in plasma is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 900%, 1000%, 1500%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 1000%, 15 ... In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the FVIII protein compared to the plasma half-life of the FVIII protein in the absence of the antibody.In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the FVIII protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to the plasma half-life of the FVIII protein in the absence of the antibody. In some embodiments, binding of an antibody disclosed herein to VWF in plasma extends the plasma half-life of the FVIII protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 700%, 800%, 900%, 1000%, 1100%, 1200%, 1300%, 1400%, 1500%, 1600%, 1700%, 1800%, 1900%, 2100%, 2200%, 2300%, 2400%, 2500%, 2600%, 2700%, 2800%, 3100%, 3200%, 3300%, 3400%, 3500%, 3600%, 3700%, 3800%, 3900%, 4100%, 4200%, 4300%, 4400%, 4500%, 4600%, 4700%, 4800%, 4900%, 5100%, 5200%, 5300%, 5400%, 5500%, 5600%, 5700%, 5800%, 5900%, 6000%, 6100%, 6200%, 6300%, 6400%, 6500%, 6600%, 6700%, 6800%, 6900%, 7000%, 7100%, 7200%, 7300%, 7400%, 7500%, 7600 In some embodiments, the antibodies disclosed herein specifically bind to a VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linkage in a 1:1 stoichiometry. In some embodiments, the antibodies disclosed herein specifically bind to a VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linkage in a 2:1 stoichiometry. In some embodiments, the antibodies disclosed herein have a dissociation constant (K) of less than 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 7 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.25 nM, 0.1 nM, 0.075 nM, 0.05 nM, 0.025 nM, 0.01 nM, or less. d) binds to the CK domain of the VWF protein. In some embodiments, the antibodies disclosed herein cross-react with VWF proteins of cynomolgus monkeys (Macaca fascicularis), house mice (Mus musculus), and / or dogs (Canis familiaris). In some embodiments, the antibodies disclosed herein have affinity for VWF proteins of cynomolgus monkeys (Macaca fascicularis), house mice (Mus musculus), and / or dogs (Canis familiaris) that is up to 10-fold (e.g., up to 10-fold, 9-fold, 8-fold, 7-fold, 6-fold, 5-fold, 4-fold, 3-fold, 2-fold, 1.5-fold, or lower) lower than the affinity of the antibody for human VWF proteins. In some embodiments, the antibodies disclosed herein are human, humanized, or chimeric antibodies. In some embodiments, the CK domain is located between amino acid positions 2,723 and 2,813 of SEQ ID NO: 1. In some embodiments, the CK domain is a CK domain of a human VWF protein having at least 85% sequence identity (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to the amino acid sequence of any one of SEQ ID NOs: 5, 6, 486, or 487. In some embodiments, the CK domain has the amino acid sequence of SEQ ID NO: 5. In some embodiments, the CK domain is a CK domain of a non-human primate (NHP) VWF protein having at least 85% sequence identity (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to the amino acid sequence of SEQ ID NO: 6. In some embodiments, the CK domain has the amino acid sequence of SEQ ID NO:6.

[0005] In certain embodiments, disclosed herein are complexes comprising a VWF protein and a monospecific antibody of the foregoing aspects and embodiments. In some embodiments, the complex comprises a VWF monomer. In some embodiments, the complex comprises a VWF dimer. In some embodiments, the complex comprises a VWF multimer. In some embodiments, the multimer is at least 250 kDa (e.g., at least 250 kDa, 500 kDa, 750 kDa, 1000 kDa, 1,250 kDa, 1,500 kDa, 1,750 kDa, 2,000 kDa, 3,000 kDa, 4,000 kDa, 5,000 kDa, 6,000 kDa, 7,000 kDa, 8,000 kDa, 9,000 kDa, 10,000 kDa). Da, 11,000kDa, 12,000kDa, 13,000kDa, 14,000kDa, 15,000kDa, 16,000kDa, 17,000kDa, 18,000kDa, 19,000kDa, 20,000kDa, 21,000kDa, 22,000kDa, 23,000kDa, 24,000kDa, 25,000kDa, or more

[0006] In certain embodiments herein, disclosed are pharmaceutical compositions comprising the monospecific antibody of the foregoing aspects and embodiments and a pharmaceutically acceptable carrier, diluent, or excipient, hi some embodiments, the pharmaceutically acceptable carrier, diluent, or excipient is selected from the group consisting of stabilizers, buffers, surfactants, bulking agents, solvents, tonicity or osmolality adjusters, antioxidants, adjuvants, and antimicrobial agents.

[0007] Certain embodiments disclosed herein are methods for treating a blood disorder characterized by excessive bleeding in a subject in need thereof, the method comprising administering to the subject a monospecific antibody or pharmaceutical composition of any of the foregoing aspects and embodiments. In some embodiments, the blood disorder is selected from the group consisting of von Willebrand disease (VWD), Heydes syndrome, hemophilia A, a platelet function disorder, and a connective tissue disorder. In some embodiments, the VWD is congenital VWD (cVWD) or acquired VWD (aVWD). In some embodiments, the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3. In some embodiments, the compositions disclosed herein treat one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) symptoms of a blood disorder selected from the group consisting of epistaxis, skin bleeding, bleeding from minor wounds, oral bleeding, angiodysplasia, gastrointestinal bleeding, bleeding from tooth extraction, postoperative bleeding, heavy menstrual bleeding, birth bleeding, hematuria, muscle hematoma, joint bleeding, visceral bleeding, and central nervous system (CNS) bleeding. In some embodiments, the compositions or pharmaceutical compositions disclosed herein promote platelet adhesion, activation, and aggregation in a subject.

[0008] In certain embodiments, disclosed herein are methods for accumulating VWF protein in the plasma of a subject in need thereof, the method comprising administering to the subject a composition comprising the monospecific antibody of any of the foregoing aspects and embodiments.

[0009] In certain embodiments, disclosed herein are methods for accumulating FVIII protein in the plasma of a subject in need thereof, the method comprising administering to the subject a composition comprising the monospecific antibody of any of the foregoing aspects and embodiments.

[0010] In certain embodiments herein, a method for increasing the plasma half-life of a VWF protein in a subject in need thereof is disclosed, the method comprising administering to the subject a composition comprising the monospecific antibody of any of the foregoing aspects and embodiments.

[0011] In certain embodiments herein, a pharmaceutical composition is disclosed comprising a monospecific antibody disclosed herein and a pharmaceutically acceptable carrier, diluent, or excipient. In some embodiments, the pharmaceutically acceptable carrier, diluent, or excipient is selected from the group consisting of stabilizers, buffers, surfactants, bulking agents, solvents, tonicity or osmolality adjusting agents, antioxidants, adjuvants, and antimicrobial agents. In some embodiments, the pharmaceutical composition disclosed herein is administered in combination with one or more (e.g., 1, 2, 3, 4, 5, or more) additional therapeutic measures. In some embodiments, the one or more additional therapeutic measures are one or more therapeutic agents. In some embodiments, the one or more additional therapeutic agents are selected from the group consisting of desmopressin (DDAVP), tranexamic acid (TXA), thalidomide, tamoxifen, ocreotide, concentrates of plasma-derived VWF protein, concentrates of VWF protein in a complex with FVIII protein (VWF; FVIII; e.g., Humate P and Wilate), concentrates of recombinant VWF protein (e.g., Vonicog alfa), concentrates of FVIII protein (e.g., Alphanate and Koate-HP), hormonal treatments (e.g., oral contraceptive pills, such as estrogen-containing contraceptives, and intrauterine devices). In some embodiments, the one or more additional therapeutic agents are surgery. In some embodiments, the one or more additional therapeutic agents are blood transfusions. In some embodiments, the one or more additional therapeutic agents are platelet transfusions. In some embodiments, the one or more additional therapeutic agents are ablation. In some embodiments, the one or more additional therapeutic agents are gene therapy. In some embodiments, the gene therapy is FVIII gene therapy.For example, the antibody or composition of the present disclosure may be administered in combination with FVIII gene therapy to extend the half-life of FVIII in the subject's plasma and / or promote the accumulation of FVIII.In some embodiments, the antibody or composition of the present disclosure is administered to patients for whom FVIII gene therapy alone is insufficient to achieve a therapeutically effective level of FVIII in plasma.In some embodiments, the antibody or composition of the present disclosure achieves a therapeutically effective level of FVIII in plasma. In some embodiments, one or more additional therapeutic agents are administered to the subject before, simultaneously with, or after administration of the composition or pharmaceutical composition. In some embodiments, one or more additional therapeutic agents are administered to the subject before administration of the composition or pharmaceutical composition. In some embodiments, one or more additional therapeutic agents are administered to the subject simultaneously with administration of the composition or pharmaceutical composition. In some embodiments, one or more additional therapeutic agents are administered to the subject after administration of the composition or pharmaceutical composition.

[0012] In certain embodiments herein, a kit is disclosed comprising the monospecific antibody or pharmaceutical composition of the aforementioned aspects and embodiments and a package insert instructing a user of the kit to carry out the method of the aforementioned aspects and embodiments.

[0013] In certain embodiments herein, the monospecific antibodies and pharmaceutical compositions of the preceding embodiments are disclosed for use as medicaments. In some embodiments, the monospecific antibodies or pharmaceutical compositions of the preceding embodiments are for use in treating a blood disorder characterized by excessive bleeding.

[0014] In certain embodiments herein, disclosed is the monospecific antibody or pharmaceutical composition of the preceding embodiments for use in treating a blood disorder characterized by excessive bleeding.

[0015] In some embodiments of the foregoing aspects, the blood disorder characterized by excessive bleeding is selected from the group consisting of VWD, Heydes syndrome, hemophilia A, platelet function disorders, and connective tissue disorders. In some embodiments, the VWD is cVWD or aVWD. In some embodiments, the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

[0016] definition Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. Generally, the immunology, oncology, cell and tissue culture, molecular biology, and protein and oligonucleotide or polynucleotide chemistry and hybridization described herein, and the nomenclature utilized in conjunction with these techniques, are well known and commonly used in the art. It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not intended to limit all claimed subject matter. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.

[0017] As used herein, the singular forms "a," "and," and "the" include the plural forms unless the context clearly dictates otherwise. Thus, for example, reference to "an antibody" includes a plurality of antibodies, and in some embodiments reference to "an antibody" includes a plurality of antibodies.

[0018] As used herein, all numerical values ​​or ranges of values ​​include whole integers within or encompassing such ranges, and fractions of values ​​or integers within or encompassing such ranges, unless the context clearly dictates otherwise. Thus, for example, a reference to a range of 90-100% includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc. In another example, a reference to a range of 1 to 5,000 times includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 times, etc., as well as 1.1, 1.2, 1.3, 1.4, 1.5 times, etc., 2.1, 2.2, 2.3, 2.4, 2.5 times, etc.

[0019] As used herein, a number preceded by "about" refers to a range that includes the number and extends from 10% below that number to 10% above that number. A range preceded by "about" refers to 10% below the lower limit of the range and extends to 10% above the upper limit of the range.

[0020] As used herein, the term "accumulation" refers to an increase in the level (e.g., concentration) of a particular protein, such as VWF or FVIII, in the blood compartment (e.g., plasma) of a subject after administration of an antibody of the present disclosure or a composition containing the same (e.g., a pharmaceutical composition) to the subject. Various factors may affect the rate of accumulation of a protein in the blood compartment of a subject, including, but not limited to, the half-life of the target protein and / or antibody in the blood compartment, the rate of sequestration of the protein by other tissues, and clearance of the protein from the body. According to the present disclosure, accumulation of a target protein (e.g., VWF or FVIII) may result in a plasma level of the protein that is at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater than the plasma level of the protein in the absence of the antibody. Alternatively, accumulation of the target protein is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 1000%, 150 ... %, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000%, or more. In some embodiments, the accumulation of a protein (e.g., VWF) results directly from the specific binding of an antibody of the present disclosure to the protein. In some embodiments, the accumulation of a protein (e.g., FVIII) results indirectly from the binding of a protein (e.g., FVIII) to another protein (e.g., VWF) bound by an antibody of the present disclosure.

[0021] As used herein, "antibody" refers to a naturally occurring or non-naturally occurring protein that binds to an antigen. Antibodies often contain variable domains and constant regions in each of their heavy and light chains. Thus, most antibodies contain a heavy chain variable domain (V) that together form the portion of the antibody that binds the antigen, sometimes referred to as the "antigen receptor." H ) and the light chain variable domain (V L Within each variable domain there are three complementarity determining regions (CDRs), V H and V L The antibody forms a loop within the antibody molecule and contacts the surface of the antigen. "Antibody" includes, but is not limited to, monoclonal antibodies, monospecific antibodies, univalent antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, chimeric antibodies, synthetic antibodies, recombinant antibodies, hybrid antibodies, mutated antibodies, grafted antibodies, antibody fragments, and in vitro generated antibodies that have antigen-binding activity. The term also includes antibody conjugates that have advantageous properties compared to non-conjugated antibodies (e.g., antibodies conjugated to half-life extending moieties, e.g., fatty acids).

[0022] As used herein, the terms "complementarity-determining region," "CDR," and "hypervariable region" refer to the portions of the variable domain in an antibody that determine the specificity with which the antibody binds to its specific antigen. A variable region of an antibody polypeptide typically contains three CDRs, usually designated CDR1, CDR2, and CDR3. More specifically, a heavy chain variable region may contain CDRs designated H1, H2, and H3, and a light chain variable region may contain CDRs L1, L2, and L3. Many methods may be used to define CDRs. Currently, various numbering schemes are used in the art, with various definitions of the length and position of CDRs. For example, the IMGT numbering scheme is a standard numbering system based on the alignment of sequences from a complete reference gene database containing the entire immunoglobulin superfamily. The Kabat numbering scheme is based on sequence alignment and uses the "variability parameter" of a given amino acid position (the number of different amino acids at a given position divided by the frequency of the majority of amino acids occurring at that position) to predict CDRs. The Chothia numbering scheme, on the other hand, is a structure-based numbering scheme in which antibody crystal structures are aligned to define loop structures as CDRs. The Martin numbering scheme focuses on the structural alignment of different framework regions of variable length. The Honneger numbering scheme (AHo's) is based on the structural alignment of the 3D structures of variable regions and uses structurally conserved Cα positions to estimate framework and CDR lengths. Those skilled in the art will note that the definition of CDRs varies depending on the method used. Therefore, the CDR sequences of a given heavy or light chain variable region may vary depending on the numbering system used. All methods of defining CDRs are contemplated for the sequences disclosed herein. Unless otherwise specified, the CDRs disclosed herein are defined according to the IMGT numbering system.

[0023] The terms "antigen-binding portion of an antibody," "antigen-binding fragment," "antigen-binding domain," and "antibody fragment" are used interchangeably herein to refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Non-limiting examples of antibody fragments encompassed within such terms include, for example, Fab fragments and V L , V H , C L , and C H1 Examples of antibodies include, but are not limited to, monovalent fragments consisting of a domain, and also include "one-arm" antibodies comprising a single heavy chain, a truncated heavy chain lacking the Fab region, and a single light chain.

[0024] As used herein, the phrase "blood disorder characterized by excessive bleeding" refers to one or more disorders in a subject (e.g., a human) that render the subject susceptible to bleeding (e.g., a bleeding diathesis). Such disorders, in some embodiments, result from conditions associated with atypical and slow blood clotting. "Blood disorders characterized by excessive bleeding" can be inherited or acquired. Platelet activation, adhesion, and / or aggregation (e.g., primary hemostasis) are impaired in some embodiments in subjects with the aforementioned disorders. In some embodiments, the function or expression of blood proteins that mediate or promote the production of insoluble cross-linked fibrin proteins during blood clotting (e.g., secondary hemostasis) is impaired in subjects with the disorder. Non-limiting examples of blood disorders characterized by excessive bleeding include von Willebrand disease (VWD), hemophilia A, platelet function disorders, and connective tissue disorders. In some embodiments, VWD is congenital VWD (cVWD) or acquired VWD (aVWD). In some embodiments, the aVWD comprises Heydes syndrome. In some embodiments, the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

[0025] As used herein, the term "altered function" when referring to a VWF protein means that the inherent function of the VWF protein is increased or decreased by a substantial amount (e.g., 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, "VWF" refers to an increase or decrease in the ability of VWF to bind to other proteins, including the binding partners described herein. VWF lacks enzymatic activity and its function is associated with binding and stabilizing other proteins involved in blood coagulation. Therefore, the function of VWF is primarily to bind to other proteins, including the binding partners described herein. Therefore, an "altered function" of VWF corresponds to an increase or decrease in the ability of VWF to bind to other proteins, such as its binding partners.

[0026] As used herein, the term "complex" refers to a molecular entity formed by two or more physically associated molecules (e.g., proteins), such as, for example, a VWF protein and an antibody described herein. The two or more molecules are associated, in some embodiments, by any physical means, including covalent bonds, ionic bonds, hydrogen bonds, and van der Waals forces. In some embodiments, the physical association between the two or more molecules is reversible. In some embodiments, the physical association between the two or more molecules is irreversible.

[0027] As used herein, the term "effective amount" refers to an amount of an antibody described herein or its antigen-binding partner that is sufficient to induce a disclosed effect when administered to a subject, e.g., to achieve treatment (e.g., accumulation of VWF and / or FVIII protein in plasma), prognosis, or diagnosis of a disease (e.g., a blood disorder characterized by excessive bleeding) as described herein. Therapeutically effective amounts of antibodies provided herein will vary depending on the relative activities of the antibodies and combinations of the disclosure (e.g., in treating, reducing, or ameliorating a disease or disorder described herein) when used alone or in combination, as well as depending on the subject and disease state being treated, the subject's weight and age, the severity of the disease state, the method of administration, etc., and in some cases will be readily determined by one of ordinary skill in the art.

[0028] As used herein, the term "monospecific" refers to an antibody that exhibits preferential affinity for one particular epitope (e.g., an epitope contained in the CK domain of a VWF protein, such as a human, NHP, mouse, or canine VWF protein).

[0029] As used herein, the term "monovalent" refers to the property of an antibody or antigen-binding fragment thereof having one antigen-binding site for a target epitope of a particular protein. For example, a monovalent antibody of the present disclosure binds to an epitope of the VWF protein (e.g., an epitope in the CK domain) through a single antigen-binding site. Within the context of the present disclosure, a monovalent antibody is, in some embodiments, a single-arm antibody (e.g., one having a heavy chain, a truncated heavy chain lacking the Fab region, and a single light chain).

[0030] As used herein, the term "one-armed antibody" or "single-armed antibody" refers to a type of monovalent antibody fragment that contains an antibody heavy chain, a truncated heavy chain lacking the Fab region, and a single light chain.

[0031] "Percent identity" and "% identity" refer to the degree to which two sequences (nucleotides or amino acids) have the same residues at the same positions in an alignment. For example, "an amino acid sequence is X% identical to SEQ ID NO: Y" refers to the % identity of an amino acid sequence to SEQ ID NO: Y, and states that X% of the residues in the amino acid sequence are identical to the residues in the sequence disclosed in SEQ ID NO: Y. Generally, computer programs are used for such calculations. Exemplary programs for comparing and aligning pairwise sequences include ALIGN (Myers and Miller, Comput Appl Biosci. 1988 March;4(1):11-7), FASTA (Pearson and Lipman, Proc Natl Acad Sci USA. 1988 April;85(8):2444-8; Pearson, Methods Enzymol. 1990;183:63-98), gapped BLAST (Altschul et al., Nucleic Acids Res 1997 September 1;25(17):3389-40), BLASTP, BLASTN, or GCG (Devereux et al., Nucleic Acids Res. 1984 January 11;12(1 Pt 1):387-95).

[0032] The term "polypeptide" refers to a chain of amino acids (e.g., naturally occurring or non-naturally occurring amino acids). In some embodiments, a polypeptide comprises naturally occurring amino acids. In some embodiments, a polypeptide comprises non-naturally occurring amino acids (e.g., cystine, desmosine, isodesmosine, hydroxyproline, hydroxylysine, gamma-carboxyglutamate, phosphoserine, phosphothreonine, phosphotyrosine, N-acetyllysine, methyllysine, inositol, L-homoalanine, L-2-aminobutyric acid, L-azidohomoalanine, β-phenylalanine, norleucine, 3-fluorotyrosine, 4-fluorophenylalanine, L-aminobutyric acid ... Polypeptides include, but are not limited to, 3,4-dihydroxyphenylalanine, pNCSF, L-(7-hydroxycoumarin-4-yl)ethylglycine, 2,3-dihydroxypropylcysteine, arylglycine, PrDiAzK, (S)-N-(2-benzoylphenyl)-1-(2-flurobenzyl)-pyrrolidine-2-carboxamide, 4-phenanthracen-9-yl-l-phenylalanine, BN tryptophan analog, p-acetylphenylalanine, and L-azidohomoalanine. Polypeptides are not limited to a specific length of the product (e.g., a polypeptide can contain at least two amino acids linked together by a peptide bond). Peptides, oligopeptides, and proteins are included in the definition of polypeptide, and such terms are used interchangeably herein unless otherwise specified. The term also encompasses peptide chains with post-expression modifications, such as glycosylation, acetylation, phosphorylation, and other modifications known in the art, both naturally occurring and non-naturally occurring. In some embodiments, the polypeptide is a whole protein or a fragment thereof.

[0033] The terms "preferentially binds" or "specifically binds" mean that an antibody or fragment thereof binds to an epitope with greater affinity than it binds to an unrelated amino acid sequence, and, if cross-reactive with other polypeptides containing the epitope, is non-toxic at levels formulated for administration to humans. In some embodiments, such affinity is at least 1.5-fold, 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 58-fold, at least 70-fold, at least 80-fold, at least 90-fold, at least 94-fold, or at least 100-fold greater than the affinity of the antibody o...

Claims

1. 1. A monospecific antibody comprising an antigen-binding site that specifically binds to an epitope of von Willebrand factor (VWF) protein located in the cysteine ​​knot (CK) domain and fragment crystallizable (Fc) region, wherein binding of the monospecific antibody to the VWF protein in plasma results in accumulation of the VWF protein in plasma compared to the plasma level of the VWF protein in the absence of the monospecific antibody.

2. The monospecific antibody of claim 1, which is a monovalent antibody.

3. The monospecific antibody of claim 1 or 2, wherein the Fc region is a wild-type Fc region.

4. The monospecific antibody of claim 1 or 2, wherein the Fc region is a modified Fc region.

5. The modified Fc region may comprise an R435H mutation, an N434A mutation, a T252L / T253S / T254F mutation, an E294delta / T307P / N434Y mutation, a T256N / A378V / S383N / N434Y mutation, an E294delta mutation, an M252Y / S254T / T256E mutation, an M428L / N434S mutation, an T307A / E380A / N434A mutation, an T250Q / M428L mutation, an T250Q / M428F mutation, an T250E / M428F mutation, an T250E / M428L mutation, an T256D / Q311V / A378V mutation, an T256D / H286D / T3 07R / Q311V / A378V mutation, H285N / T307Q / N315D mutation, T307Q / Q311V / A378V mutation, H285D / T307Q / A378V mutation, L234F / L235E / P331S mutation, L234F / L235Q / K322Q mutation, L234F / L235Q / P331G mutation, L234F / L235A / K322Q mutation, S228P / F234A / L235A / G237A / P238S mutation, L234A / L235E / G237A / A330S / P331S mutation, F243A / V264A mutation, S228P / L235E / P329G mutation, M252Y / M428L mutation, D259I / V308F mutation, T307Q / N434S mutation, M428L / V308F mutation, Q311V / N434S mutation, H433K / N434F mutation, E258F / V427T mutation, K288E / H435K mutation, F234A / L235A mutation, F234A / L235A / S228P mutation, L234A / L235A / P329G mutation, F234A / L235A / P329G mutation, P329G mutation, F234 mutation, S228P mutation, delta-K447 mutation, L235A mutation, L235E mutation, V308 P mutation, V308W mutation, V308Y mutation, V308F mutation, N434S mutation, T307 mutation, Q312A mutation, K322A mutation, P329A mutation, P331A mutation, P238A mutation, D265A mutation, D269A mutation, D270A mutation, N297A mutation, A327Q mutation, P329A mutation, S239A mutation, E294A mutation, Q295A mutation, V303A mutation, A330R mutation, T299A mutation, F234A mutation, T366W mutation, T366S mutation, L368A mutation, Y407V mutation, F405L mutation, K409R mutation, F405L / R409K mutation,5. The monospecific antibody of claim 4, comprising one or more mutations selected from the group consisting of:

6. The monospecific antibody of any one of claims 1 to 5, wherein the modified Fc region is N-terminally truncated.

7. The modified Fc region is 7. The monospecific antibody of claim 6, wherein the monospecific antibody is N-terminally truncated by 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more amino acid residues.

8. The monospecific antibody of any one of claims 1 to 7, which is a human IgG4 antibody comprising a first heavy chain and a second heavy chain.

9. 9. The monospecific antibody of claim 8, wherein the first heavy chain comprises S228P / T366W / F234A / L235A / delta-K447 mutations and the second heavy chain comprises S228P / T366S / L368A / Y407V / F234A / L235A / delta-K447 mutations.

10. 9. The monospecific antibody of claim 8, wherein the first heavy chain comprises S228P / T366W / delta-K447 mutations and the second heavy chain comprises S228P / T366S / L368A / Y407V / delta-K447 mutations.

11. 11. The monospecific antibody of claim 9 or 10, wherein the first heavy chain and the second heavy chain further comprise M252Y / S254T / T256E mutations.

12. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

16.

13. 13. The monospecific antibody of any one of claims 1 to 12, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

16.

14. 14. The monospecific antibody of any one of claims 1 to 13, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

16.

15. 15. The monospecific antibody of any one of claims 1 to 14, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

16.

16. 16. The monospecific antibody of any one of claims 1 to 15, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

16.

17. 17. The monospecific antibody of any one of claims 1 to 16, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 15, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

18.

18. 18. The monospecific antibody of any one of claims 1 to 17, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 12 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 15; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 16 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

18.

19. 19. The monospecific antibody of any one of claims 1 to 18, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 453, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 473, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

463.

20. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

23.

21. 21. The monospecific antibody of any one of claims 1 to 11 and 20, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

23.

22. 22. The monospecific antibody of any one of claims 1 to 11, 20 and 21, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

23.

23. 23. The monospecific antibody of any one of claims 1 to 11 and 20 to 22, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

23.

24. 24. The monospecific antibody of any one of claims 1 to 11 and 20 to 23, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

23.

25. 25. The monospecific antibody of any one of claims 1 to 11 and 20 to 24, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 22, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

25.

26. 26. The monospecific antibody of any one of claims 1 to 11 and 20 to 25, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 19 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 22; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 23 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

25.

27. 27. The monospecific antibody of any one of claims 1 to 11 and 20 to 26, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 454, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 474, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

464.

28. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

30.

29. 29. The monospecific antibody of any one of claims 1 to 11 and 28, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

30.

30. 30. The monospecific antibody of any one of claims 1 to 11, 28 and 29, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

30.

31. 31. The monospecific antibody of any one of claims 1 to 11 and 28 to 30, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

30.

32. 32. The monospecific antibody of any one of claims 1 to 11 and 28 to 31, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

30.

33. 33. The monospecific antibody of any one of claims 1 to 11 and 28 to 32, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 29, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

32.

34. 34. The monospecific antibody of any one of claims 1 to 11 and 28 to 33, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 26 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 29; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 30 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

32.

35. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

37.

36. 36. The monospecific antibody of any one of claims 1 to 11 and 35, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

37.

37. 37. The monospecific antibody of any one of claims 1 to 11, 35 and 36, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

37.

38. 38. The monospecific antibody of any one of claims 1 to 11 and 35 to 37, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

37.

39. 39. The monospecific antibody of any one of claims 1 to 11 and 35 to 38, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

37.

40. 40. The monospecific antibody of any one of claims 1 to 11 and 35 to 39, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 36, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

39.

41. 41. The monospecific antibody of any one of claims 1 to 11 and 35 to 40, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 33 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 36; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 37 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 38, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

39.

42. 42. The monospecific antibody of any one of claims 1 to 11 and 35 to 41, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 455, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 475, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

465.

43. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

44.

44. 44. The monospecific antibody of any one of claims 1 to 11 and 43, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

44.

45. 45. The monospecific antibody of any one of claims 1 to 11, 43 and 44, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

44.

46. 46. ​​The monospecific antibody of any one of claims 1 to 11 and 43 to 45, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

44.

47. 47. The monospecific antibody of any one of claims 1 to 11 and 43 to 46, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

44.

48. 48. The monospecific antibody of any one of claims 1 to 11 and 43 to 47, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 43, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 45, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GSS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

46.

49. 49. The monospecific antibody of any one of claims 1 to 11 and 43 to 48, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 40, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 43; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 44, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 45, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GSS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

46.

50. 50. The monospecific antibody of any one of claims 1 to 11 and 43 to 49, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 456, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 476, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

466.

51. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

51.

52. 52. The monospecific antibody of any one of claims 1 to 11 and 51, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

51.

53. 53. The monospecific antibody of any one of claims 1 to 11, 51 and 52, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

51.

54. 54. The monospecific antibody of any one of claims 1 to 11 and 51 to 53, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

51.

55. 55. The monospecific antibody of any one of claims 1 to 11 and 51 to 54, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

51.

56. 56. The monospecific antibody of any one of claims 1 to 11 and 51 to 55, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 48, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 49, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 50, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 52, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

53.

57. 57. The monospecific antibody of any one of claims 1 to 11 and 51 to 56, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 47 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 48, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 49, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 50; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 51 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 52, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

53.

58. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

58.

59. 59. The monospecific antibody of any one of claims 1 to 11 and 58, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

58.

60. 60. The monospecific antibody of any one of claims 1 to 11, 58 and 59, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

58.

61. 61. The monospecific antibody of any one of claims 1 to 11 and 58 to 60, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

58.

62. 62. The monospecific antibody of any one of claims 1 to 11 and 58 to 61, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

58.

63. 63. The monospecific antibody of any one of claims 1 to 11 and 58 to 62, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 57, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 59, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

60.

64. 64. The monospecific antibody of any one of claims 1 to 11 and 58 to 63, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 54 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 57; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 58 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 59, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

60.

65. 65. The monospecific antibody of any one of claims 1 to 11 and 58 to 64, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 457, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 577, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

567.

66. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

65.

67. 67. The monospecific antibody of any one of claims 1 to 11 and 66, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 61, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

65.

68. 68. The monospecific antibody of any one of claims 1 to 11, 66 and 67, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

65.

69. 69. The monospecific antibody of any one of claims 1 to 11 and 66 to 68, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

65.

70. 70. The monospecific antibody of any one of claims 1 to 11 and 66 to 69, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

65.

71. 71. The monospecific antibody of any one of claims 1 to 11 and 66 to 70, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

67.

72. 72. The monospecific antibody of any one of claims 1 to 11 and 66 to 71, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 61 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 65 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

67.

73. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

65.

74. 74. The monospecific antibody of any one of claims 1 to 11 and 73, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

65.

75. 75. The monospecific antibody of any one of claims 1 to 11, 73 and 74, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

65.

76. 76. The monospecific antibody of any one of claims 1 to 11 and 73 to 75, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

65.

77. 77. The monospecific antibody of any one of claims 1 to 11 and 73 to 76, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

65.

78. 78. The monospecific antibody of any one of claims 1 to 11 and 73 to 77, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

67.

79. 79. The monospecific antibody of any one of claims 1 to 11 and 73 to 78, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 61 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 65 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

67.

80. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

72.

81. 81. The monospecific antibody of any one of claims 1 to 11 and 80, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

72.

82. 82. The monospecific antibody of any one of claims 1 to 11, 80 and 81, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

72.

83. 83. The monospecific antibody of any one of claims 1 to 11 and 80 to 82, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

72.

84. 84. The monospecific antibody of any one of claims 1 to 11 and 80 to 83, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

72.

85. 85. The monospecific antibody of any one of claims 1 to 11 and 80 to 84, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 71, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

74.

86. 86. The monospecific antibody of any one of claims 1 to 11 and 80 to 85, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 68 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 71; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 72 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

74.

87. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

79.

88. 88. The monospecific antibody of any one of claims 1 to 11 and 87, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 75, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

79.

89. 89. The monospecific antibody of any one of claims 1 to 11, 87 and 88, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

79.

90. 90. The monospecific antibody of any one of claims 1 to 11 and 87 to 89, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

79.

91. 91. The monospecific antibody of any one of claims 1 to 11 and 87 to 90, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

79.

92. 92. The monospecific antibody of any one of claims 1 to 11 and 87 to 91, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 78, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 80, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

81.

93. 93. The monospecific antibody of any one of claims 1 to 11 and 87 to 92, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 75 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 78; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 79 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 80, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

81.

94. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

86.

95. 95. The monospecific antibody of any one of claims 1 to 11 and 94, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 82, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

86.

96. 96. The monospecific antibody of any one of claims 1 to 11, 94 and 95, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

86.

97. 97. The monospecific antibody of any one of claims 1 to 11 and 94 to 96, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 82, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

86.

98. 98. The monospecific antibody of any one of claims 1 to 11 and 94 to 97, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

86.

99. 99. The monospecific antibody of any one of claims 1 to 11 and 94 to 98, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 83, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 85, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 87, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

88.

100. 100% identical to the amino acid sequence of SEQ ID NO: 86, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence of SEQ ID NO: 87, CDR L2 having an amino acid sequence of 100% identical to the amino acid sequence of SEQ ID NO: 87, CDR L3 having an amino acid sequence of 100% identical to the amino acid sequence of SEQ ID NO:

88.

101. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

93.

102. 102. The monospecific antibody of any one of claims 1 to 11 and 101, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

93.

103. 103. The monospecific antibody of any one of claims 1 to 11, 101 and 102, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

93.

104. 104. The monospecific antibody of any one of claims 1 to 11 and 101 to 103, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

93.

105. 105. The monospecific antibody of any one of claims 1 to 11 and 101 to 104, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

93.

106. 106. The monospecific antibody of any one of claims 1 to 11 and 101 to 105, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 92, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 94, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

95.

107. 107. The monospecific antibody of any one of claims 1 to 11 and 101 to 106, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 89 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 92; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 93 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 94, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

95.

108. 108. The monospecific antibody of any one of claims 1 to 11 and 101 to 107, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 458, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 478, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

468.

109. 12. The monospecific antibody according to any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

100.

110. 110. The monospecific antibody of any one of claims 1 to 11 and 109, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 96, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

100.

111. 111. The monospecific antibody of any one of claims 1 to 11, 109 and 110, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

100.

112. 112. The monospecific antibody of any one of claims 1 to 11 and 109 to 111, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 96, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

100.

113. 113. The monospecific antibody of any one of claims 1 to 11 and 109 to 112, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 96, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

100.

114. 114. The monospecific antibody of any one of claims 1 to 11 and 109 to 113, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 99, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

102.

115. 115. The monospecific antibody of any one of claims 1 to 11 and 109 to 114, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 96 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 99; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 100 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

102.

116. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

107.

117. 117. The monospecific antibody of any one of claims 1 to 11 and 116, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 103, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

107.

118. 118. The monospecific antibody of any one of claims 1 to 11, 116 and 117, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 103, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

107.

119. 119. The monospecific antibody of any one of claims 1 to 11 and 116 to 118, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 103, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

107.

120. 120. The monospecific antibody of any one of claims 1 to 11 and 116 to 119, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 103, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

107.

121. 121. The monospecific antibody of any one of claims 1 to 11 and 116 to 120, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 106, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

109.

122. 122. The monospecific antibody of any one of claims 1 to 11 and 116 to 121, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 103 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 106; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 107 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

109.

123. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 110, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

114.

124. 124. The monospecific antibody of any one of claims 1 to 11 and 123, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 110, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

114.

125. 125. The monospecific antibody of any one of claims 1 to 11, 123 and 124, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

114.

126. 126. The monospecific antibody of any one of claims 1 to 11 and 123 to 125, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 110, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

114.

127. 127. The monospecific antibody of any one of claims 1 to 11 and 123 to 126, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 110, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

114.

128. 128. The monospecific antibody of any one of claims 1 to 11 and 123 to 127, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 113, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

116.

129. 129. The monospecific antibody of any one of claims 1 to 11 and 123 to 128, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 110 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 113; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 114 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

116.

130. 130. The monospecific antibody of any one of claims 1 to 11 and 123 to 129, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 459, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 479, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

469.

131. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 117, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

121.

132. 132. The monospecific antibody of any one of claims 1 to 11 and 131, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 117, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

121.

133. 133. The monospecific antibody of any one of claims 1 to 11, 131 and 132, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

121.

134. 134. The monospecific antibody of any one of claims 1 to 11 and 131 to 133, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 117, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

121.

135. 135. The monospecific antibody of any one of claims 1 to 11 and 131 to 134, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

121.

136. 136. The monospecific antibody of any one of claims 1 to 11 and 131 to 135, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 120, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

123.

137. 137. The monospecific antibody of any one of claims 1 to 11 and 131 to 136, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 117 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 120; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 121 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

123.

138. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

128.

139. 139. The monospecific antibody of any one of claims 1 to 11 and 138, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 124, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

128.

140. 140. The monospecific antibody of any one of claims 1 to 11, 138 and 139, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

128.

141. 141. The monospecific antibody of any one of claims 1 to 11 and 138 to 140, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

128.

142. 142. The monospecific antibody of any one of claims 1 to 11 and 138 to 141, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

128.

143. 143. The monospecific antibody of any one of claims 1 to 11 and 138 to 142, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 127, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

130.

144. 144. The monospecific antibody of any one of claims 1 to 11 and 138 to 143, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 124 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 127; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 128 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

131.

145. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 131, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

135.

146. 146. The monospecific antibody of any one of claims 1 to 11 and 145, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 131, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

135.

147. 147. The monospecific antibody of any one of claims 1 to 11, 145 and 146, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

135.

148. 148. The monospecific antibody of any one of claims 1 to 11 and 145 to 147, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 131, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

135.

149. 149. The monospecific antibody of any one of claims 1 to 11 and 145 to 148, comprising a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

135.

150. 150. The monospecific antibody of any one of claims 1 to 11 and 145 to 149, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 134, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

137.

151. 151. The monospecific antibody of any one of claims 1 to 11 and 145 to 150, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 131 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 134; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 135 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

137.

152. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 138, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

142.

153. 153. The monospecific antibody of any one of claims 1 to 11 and 152, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 138, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

142.

154. 154. The monospecific antibody of any one of claims 1 to 11, 152 and 153, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

142.

155. 154. The monospecific antibody of any one of claims 1 to 11 and 152 to 153, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 138, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

142.

156. 155. The monospecific antibody of any one of claims 1 to 11 and 152 to 154, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 138, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

142.

157. 157. The monospecific antibody of any one of claims 1 to 11 and 152 to 156, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 141, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

144.

158. 158. The monospecific antibody of any one of claims 1 to 11 and 152 to 157, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 138 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 141; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 142 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

144.

159. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 145, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

149.

160. 160. The monospecific antibody of any one of claims 1 to 11 and 159, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 145, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

149.

161. 161. The monospecific antibody of any one of claims 1 to 11, 159 and 160, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

149.

162. 162. The monospecific antibody of any one of claims 1 to 11 and 159 to 161, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 145, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

149.

163. 163. The monospecific antibody of any one of claims 1 to 11 and 159 to 162, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 145, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

149.

164. 164. The monospecific antibody of any one of claims 1 to 11 and 159 to 163, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 148, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

151.

165. 165. The monospecific antibody of any one of claims 1 to 11 and 159 to 164, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 145 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 148; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 149 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

151.

166. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 152, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

156.

167. 167. The monospecific antibody of any one of claims 1 to 11 and 166, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 152, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

156.

168. 168. The monospecific antibody of any one of claims 1 to 11, 166 and 167, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

156.

169. 169. The monospecific antibody of any one of claims 1 to 11 and 166 to 168, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 152, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

156.

170. 170. The monospecific antibody of any one of claims 1 to 11 and 166 to 169, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 152, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

156.

171. 170. The monospecific antibody of any one of claims 1 to 11 and 166 to 170, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 155, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

158.

172. 172. The monospecific antibody of any one of claims 1 to 11 and 166 to 171, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 152 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 155; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 156 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

158.

173. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 159, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

163.

174. 174. The monospecific antibody of any one of claims 1 to 11 and 173, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 159, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

163.

175. 174. The monospecific antibody of any one of claims 1 to 11, 173 and 173, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

163.

176. 176. The monospecific antibody of any one of claims 1 to 11 and 173 to 175, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 159, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

163.

177. 177. The monospecific antibody of any one of claims 1 to 11 and 173 to 176, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 159, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

163.

178. 178. The monospecific antibody of any one of claims 1 to 11 and 173 to 177, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 162, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

165.

179. 172. The monospecific antibody of any one of claims 1 to 11 and 166 to 171, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 159, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 162; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 163, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

165.

180. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 166, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

170.

181. 181. The monospecific antibody of any one of claims 1 to 11 and 180, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 166, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

170.

182. 182. The monospecific antibody of any one of claims 1 to 11, 180 and 181, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

170.

183. 183. The monospecific antibody of any one of claims 1 to 11 and 180 to 182, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 166, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

170.

184. 184. The monospecific antibody of any one of claims 1 to 11 and 180 to 183, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 166, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

170.

185. 185. The monospecific antibody of any one of claims 1 to 11 and 180 to 184, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 169, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

172.

186. 186. The monospecific antibody of any one of claims 1 to 11 and 180 to 185, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 166 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 169; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 170 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

172.

187. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 173, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

177.

188. 188. The monospecific antibody of any one of claims 1 to 11 and 187, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 173, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

177.

189. 189. The monospecific antibody of any one of claims 1 to 11, 187, and 187 to 188, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

177.

190. 190. The monospecific antibody of any one of claims 1 to 11 and 187 to 189, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 173, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

177.

191. 191. The monospecific antibody of any one of claims 1 to 11 and 187 to 190, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 173, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

177.

192. 192. The monospecific antibody of any one of claims 1 to 11 and 187 to 191, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 176, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 178, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

179.

193. 193. The monospecific antibody of any one of claims 1 to 11 and 187 to 192, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 173 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 176; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 177 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 178, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

179.

194. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 180, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

184.

195. 195. The monospecific antibody of any one of claims 1 to 11 and 194, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 180, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

184.

196. 196. The monospecific antibody of any one of claims 1 to 11, 194 and 195, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

184.

197. 197. The monospecific antibody of any one of claims 1 to 11 and 194 to 196, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 180, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

184.

198. 198. The monospecific antibody of any one of claims 1 to 11 and 194 to 197, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 180, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

184.

199. 200. The monospecific antibody of any one of claims 1 to 11 and 194 to 198, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 183, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

186.

200. 200. The monospecific antibody of any one of claims 1 to 11 and 194 to 199, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 180, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 183; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 184, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

186.

201. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 187, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

191.

202. 202. The monospecific antibody of any one of claims 1 to 11 and 201, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 187, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

191.

203. 203. The monospecific antibody of any one of claims 1 to 11, 201 and 202, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 187, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

191.

204. 204. The monospecific antibody of any one of claims 1 to 11 and 201 to 203, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 187, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

191.

205. 205. The monospecific antibody of any one of claims 1 to 11 and 201 to 204, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 187, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

191.

206. a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 190; 206. The monospecific antibody of any one of claims 1 to 11 and 201 to 205, comprising a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

193.

207. 207. The monospecific antibody of any one of claims 1 to 11 and 201 to 206, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 187 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 190; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 191 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

193.

208. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 194, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

198.

209. 209. The monospecific antibody of any one of claims 1 to 11 and 208, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 194, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

198.

210. 209. The monospecific antibody of any one of claims 1 to 11, 208 and 209, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 194, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

198.

211. 211. The monospecific antibody of any one of claims 1 to 11 and 208 to 210, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 194, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

198.

212. 212. The monospecific antibody of any one of claims 1 to 11 and 208 to 211, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 194, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

198.

213. 213. The monospecific antibody of any one of claims 1 to 11 and 208 to 212, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 197, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

200.

214. 214. The monospecific antibody of any one of claims 1 to 11 and 208 to 213, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 194 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 197; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 198 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

200.

215. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 201, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

205.

216. 216. The monospecific antibody of any one of claims 1 to 11 and 215, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 201, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

205.

217. 217. The monospecific antibody of any one of claims 1 to 11, 215 and 216, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 201, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

205.

218. 218. The monospecific antibody of any one of claims 1 to 11 and 215 to 217, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 201, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

205.

219. 219. The monospecific antibody of any one of claims 1 to 11 and 215 to 218, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 201, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

205.

220. 220. The monospecific antibody of any one of claims 1 to 11 and 215 to 219, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 204, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 206, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GVD, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

207.

221. 221. The monospecific antibody of any one of claims 1 to 11 and 215 to 220, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 201, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 204; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 205, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 206, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GVD, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

207.

222. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 208, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

212.

223. 223. The monospecific antibody of any one of claims 1 to 11 and 222, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 208, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

212.

224. 224. The monospecific antibody of any one of claims 1 to 11, 222 and 223, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 208, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

212.

225. 225. The monospecific antibody of any one of claims 1 to 11 and 222 to 224, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 208, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

212.

226. 226. The monospecific antibody of any one of claims 1 to 11 and 222 to 225, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 208, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

212.

227. 227. The monospecific antibody of any one of claims 1 to 11 and 222 to 226, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 211, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 212, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

213.

228. 228. The monospecific antibody of any one of claims 1 to 11 and 222 to 227, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 208 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 211; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 212 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 212, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

213.

229. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 215, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

219.

230. 230. The monospecific antibody of any one of claims 1 to 11 and 229, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 215, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

219.

231. 204. The monospecific antibody of any one of claims 1 to 11, 229 and 203, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 215, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

219.

232. 232. The monospecific antibody of any one of claims 1 to 11 and 229 to 231, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 215, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

219.

233. 233. The monospecific antibody of any one of claims 1 to 11 and 229 to 232, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 215, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

219.

234. 234. The monospecific antibody of any one of claims 1 to 11 and 229 to 233, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 218, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

221.

235. 235. The monospecific antibody of any one of claims 1 to 11 and 229 to 234, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 215 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 218; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 219 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

221.

236. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 222, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

226.

237. 237. The monospecific antibody of any one of claims 1 to 11 and 236, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 222, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

226.

238. 238. The monospecific antibody of any one of claims 1 to 11, 236 and 237, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 222, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

226.

239. 239. The monospecific antibody of any one of claims 1 to 11 and 236 to 238, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 222, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

226.

240. 240. The monospecific antibody of any one of claims 1 to 11 and 236 to 239, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 222, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

226.

241. 241. The monospecific antibody of any one of claims 1 to 11 and 236 to 240, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 225, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 227, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

228.

242. 242. The monospecific antibody of any one of claims 1 to 11 and 236 to 241, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 222 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 225; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 226 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 227, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

228.

243. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 229, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

233.

244. 244. The monospecific antibody of any one of claims 1 to 11 and 243, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 229, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

233.

245. 245. The monospecific antibody of any one of claims 1 to 11, 243 and 244, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 229, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

233.

246. 246. The monospecific antibody of any one of claims 1 to 11 and 243 to 245, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 229, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

233.

247. 247. The monospecific antibody of any one of claims 1 to 11 and 243 to 246, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 229, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

233.

248. 248. The monospecific antibody of any one of claims 1 to 11 and 243 to 247, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 232, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 234, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

235.

249. 249. The monospecific antibody of any one of claims 1 to 11 and 243 to 248, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 229, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 232; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 233, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 234, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

235.

250. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 236, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

240.

251. 251. The monospecific antibody of any one of claims 1 to 11 and 250, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 236, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

240.

252. 252. The monospecific antibody of any one of claims 1 to 11, 250 and 251, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

240.

253. 253. The monospecific antibody of any one of claims 1 to 11 and 250 to 252, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 236, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

240.

254. 254. The monospecific antibody of any one of claims 1 to 11 and 250 to 253, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 236, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

240.

255. 255. The monospecific antibody of any one of claims 1 to 11 and 250 to 254, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 239, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

242.

256. 256. The monospecific antibody of any one of claims 1 to 11 and 250 to 255, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 236 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 239; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 240 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

242.

257. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 243, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

247.

258. 258. The monospecific antibody of any one of claims 1 to 11 and 257, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 243, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

247.

259. 259. The monospecific antibody of any one of claims 1 to 11, 257 and 258, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 243, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

247.

260. 260. The monospecific antibody of any one of claims 1 to 11 and 257 to 259, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 243, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

247.

261. 261. The monospecific antibody of any one of claims 1 to 11 and 257 to 260, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 243, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

247.

262. 262. The monospecific antibody of any one of claims 1 to 11 and 257 to 261, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 246, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

249.

263. 263. The monospecific antibody of any one of claims 1 to 11 and 257 to 262, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 243, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 244, CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 245, and CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 246; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 247, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 248, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

249.

264. 264. The monospecific antibody of any one of claims 1 to 11 and 257 to 263, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 460, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 480, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

470.

265. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 250, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

254.

266. 266. The monospecific antibody of any one of claims 1 to 11 and 265, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 250, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

254.

267. 267. The monospecific antibody of any one of claims 1 to 11, 265 and 266, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 250, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

254.

268. 268. The monospecific antibody of any one of claims 1 to 11 and 265 to 267, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 250, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

254.

269. 269. The monospecific antibody of any one of claims 1 to 11 and 265 to 268, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 250, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

254.

270. 269. The monospecific antibody of any one of claims 1 to 11 and 265 to 269, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 253, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

256.

271. 271. The monospecific antibody of any one of claims 1 to 11 and 265 to 270, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 250, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 253; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 254, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

256.

272. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 257, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

261.

273. 273. The monospecific antibody of any one of claims 1 to 11 and 272, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 257, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

261.

274. 274. The monospecific antibody of any one of claims 1 to 11, 272 and 273, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 257, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

261.

275. 275. The monospecific antibody of any one of claims 1 to 11 and 272 to 274, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 257, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

261.

276. 276. The monospecific antibody of any one of claims 1 to 11 and 272 to 275, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 257, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

261.

277. 277. The monospecific antibody of any one of claims 1 to 11 and 272 to 276, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 260, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

263.

278. 278. The monospecific antibody of any one of claims 1 to 11 and 272 to 277, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 257 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 260; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 261 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

263.

279. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 264, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

268.

280. 279. The monospecific antibody of any one of claims 1 to 11 and 279, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 264, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

268.

281. 281. The monospecific antibody of any one of claims 1 to 11, 279 and 280, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 264, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

268.

282. 282. The monospecific antibody of any one of claims 1 to 11 and 279 to 281, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 264, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

268.

283. 283. The monospecific antibody of any one of claims 1 to 11 and 279 to 282, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 264, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

268.

284. 284. The monospecific antibody of any one of claims 1 to 11 and 279 to 283, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 267, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 269, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

270.

285. 285. The monospecific antibody of any one of claims 1 to 11 and 279 to 284, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 264, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 267; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 268, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 269, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

270.

286. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 271, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

275.

287. 287. The monospecific antibody of any one of claims 1 to 11 and 286, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 271, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

275.

288. 288. The monospecific antibody of any one of claims 1 to 11, 286 and 287, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 271, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

275.

289. 289. The monospecific antibody of any one of claims 1 to 11 and 286 to 288, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 271, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

275.

290. 289. The monospecific antibody of any one of claims 1 to 11 and 286 to 289, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 271, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

275.

291. 291. The monospecific antibody of any one of claims 1 to 11 and 286 to 290, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 274, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

277.

292. 292. The monospecific antibody of any one of claims 1 to 11 and 286 to 291, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 271, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 274; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 275, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

277.

293. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 278, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

282.

294. 294. The monospecific antibody of any one of claims 1 to 11 and 293, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 278, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

282.

295. 295. The monospecific antibody of any one of claims 1 to 11, 293 and 294, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 278, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

282.

296. 296. The monospecific antibody of any one of claims 1 to 11 and 293 to 295, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 278, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

282.

297. 300. The monospecific antibody of any one of claims 1 to 11 and 293 to 296, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 278, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

282.

298. 300. The monospecific antibody of any one of claims 1 to 11 and 293 to 297, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 281, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

284.

299. 300. The monospecific antibody of any one of claims 1 to 11 and 293 to 298, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 278 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 281; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 282 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

284.

300. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 285, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

289.

301. 301. The monospecific antibody of any one of claims 1 to 11 and 300, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 285, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

289.

302. 302. The monospecific antibody of any one of claims 1 to 11, 300 and 301, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 285, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

289.

303. 303. The monospecific antibody of any one of claims 1 to 11 and 300 to 302, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 285, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

289.

304. 304. The monospecific antibody of any one of claims 1 to 11 and 300 to 303, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 285, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

289.

305. 306. The monospecific antibody of any one of claims 1 to 11 and 300 to 304, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 288, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

291.

306. 306. The monospecific antibody of any one of claims 1 to 11 and 300 to 305, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO:285, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:286, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:287, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:288; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:289, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:290, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

291.

307. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 292, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

296.

308. 308. The monospecific antibody of any one of claims 1 to 11 and 307, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 292, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

296.

309. 309. The monospecific antibody of any one of claims 1 to 11, 307 and 308, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 292, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

296.

310. 310. The monospecific antibody of any one of claims 1 to 11 and 307 to 309, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 292, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

296.

311. 311. The monospecific antibody of any one of claims 1 to 11 and 307 to 310, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 292, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

296.

312. 312. The monospecific antibody of any one of claims 1 to 11 and 307 to 311, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 295, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 297, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

298.

313. 313. The monospecific antibody of any one of claims 1 to 11 and 307 to 312, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO:292 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:293, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:294, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:295; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:296 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:297, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

298.

314. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 299, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

303.

315. 315. The monospecific antibody of any one of claims 1 to 11 and 314, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 299, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

303.

316. 316. The monospecific antibody of any one of claims 1 to 11, 314 and 315, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 299, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

303.

317. 317. The monospecific antibody of any one of claims 1 to 11 and 314 to 316, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 299, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

303.

318. 318. The monospecific antibody of any one of claims 1 to 11 and 314 to 317, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 299, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

303.

319. 319. The monospecific antibody of any one of claims 1 to 11 and 314 to 318, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 302, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

305.

320. 320. The monospecific antibody of any one of claims 1 to 11 and 314 to 319, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 299 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 302; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 303 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

305.

321. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 306, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

310.

322. 322. The monospecific antibody of any one of claims 1 to 11 and 321, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 306, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

310.

323. 323. The monospecific antibody of any one of claims 1 to 11, 321 and 322, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 306, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

310.

324. 324. The monospecific antibody of any one of claims 1 to 11 and 321 to 323, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 306, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

310.

325. 325. The monospecific antibody of any one of claims 1 to 11 and 321 to 324, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 306, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

310.

326. 326. The monospecific antibody of any one of claims 1 to 11 and 321 to 325, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 309, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

312.

327. 327. The monospecific antibody of any one of claims 1 to 11 and 321 to 326, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 306, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 309; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 310, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

312.

328. 328. The monospecific antibody of any one of claims 1 to 11 and 321 to 327, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 461, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 481, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

471.

329. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 313, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

317.

330. 330. The monospecific antibody of any one of claims 1 to 11 and 329, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 313, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

317.

331. 331. The monospecific antibody of any one of claims 1 to 11, 329 and 330, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 313, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

317.

332. 332. The monospecific antibody of any one of claims 1 to 11 and 329 to 331, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 313, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

317.

333. 332. The monospecific antibody of any one of claims 1 to 11 and 329 to 332, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 313, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

317.

334. 336. The monospecific antibody of any one of claims 1 to 11 and 329 to 333, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 316, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

319.

335. 336. The monospecific antibody of any one of claims 1 to 11 and 329 to 334, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 313 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 316; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 317 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

319.

336. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 320, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

324.

337. 337. The monospecific antibody of any one of claims 1 to 11 and 336, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 320, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

324.

338. 338. The monospecific antibody of any one of claims 1 to 11, 336 and 337, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 320, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

324.

339. 339. The monospecific antibody of any one of claims 1 to 11 and 336 to 338, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 320, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

324.

340. 340. The monospecific antibody of any one of claims 1 to 11 and 336 to 339, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 320, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

324.

341. 340. The monospecific antibody of any one of claims 1 to 11 and 336 to 340, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 323, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

326.

342. 342. The monospecific antibody of any one of claims 1 to 11 and 336 to 341, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 320, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 323; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 324, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

326.

343. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 327, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

331.

344. 344. The monospecific antibody of any one of claims 1 to 11 and 343, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 327, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

331.

345. 345. The monospecific antibody of any one of claims 1 to 11, 343 and 344, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 327, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

331.

346. 346. The monospecific antibody of any one of claims 1 to 11 and 343 to 345, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 327, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

331.

347. 347. The monospecific antibody of any one of claims 1 to 11 and 343 to 346, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 327, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

331.

348. 347. The monospecific antibody of any one of claims 1 to 11 and 343 to 347, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 330, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

333.

349. 349. The monospecific antibody of any one of claims 1 to 11 and 343 to 348, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 327 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 330; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 331 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

333.

350. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 334, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

338.

351. 351. The monospecific antibody of any one of claims 1 to 11 and 350, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 334, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

338.

352. 352. The monospecific antibody of any one of claims 1 to 11, 350 and 351, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 334, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

338.

353. 353. The monospecific antibody of any one of claims 1 to 11 and 350 to 352, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 334, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

338.

354. 354. The monospecific antibody of any one of claims 1 to 11 and 350 to 353, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 334, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

338.

355. 355. The monospecific antibody of any one of claims 1 to 11 and 350 to 354, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 337, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

340.

356. 356. The monospecific antibody of any one of claims 1 to 11 and 350 to 355, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 334 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 337; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 338 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

340.

357. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 341, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

345.

358. 358. The monospecific antibody of any one of claims 1 to 11 and 357, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 341, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

345.

359. 359. The monospecific antibody of any one of claims 1 to 11, 357 and 358, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 341, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

345.

360. 360. The monospecific antibody of any one of claims 1 to 11 and 357 to 359, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 341, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

345.

361. 361. The monospecific antibody of any one of claims 1 to 11 and 357 to 360, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 341, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

345.

362. 362. The monospecific antibody of any one of claims 1 to 11 and 357 to 361, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 344, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

347.

363. 362. The monospecific antibody of any one of claims 1 to 11 and 357 to 362, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 341 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 344; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 345 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

347.

364. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 348, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

352.

365. 365. The monospecific antibody of any one of claims 1 to 11 and 364, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 348, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

352.

366. 366. The monospecific antibody of any one of claims 1 to 11, 364 and 365, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 348, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

352.

367. 367. The monospecific antibody of any one of claims 1 to 11 and 364 to 366, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 348, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

352.

368. 368. The monospecific antibody of any one of claims 1 to 11 and 364 to 367, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 348, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

352.

369. 369. The monospecific antibody of any one of claims 1 to 11 and 364 to 368, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 351, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

354.

370. 369. The monospecific antibody of any one of claims 1 to 11 and 364 to 369, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 348 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 351; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 352 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

354.

371. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 355, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

359.

372. 372. The monospecific antibody of any one of claims 1 to 11 and 371, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 355, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

359.

373. 373. The monospecific antibody of any one of claims 1 to 11, 371 and 372, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 355, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

359.

374. 374. The monospecific antibody of any one of claims 1 to 11 and 371 to 373, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 355, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

359.

375. 375. The monospecific antibody of any one of claims 1 to 11 and 371 to 374, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 355, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

359.

376. 376. The monospecific antibody of any one of claims 1 to 11 and 371 to 375, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 358, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

361.

377. 376. The monospecific antibody of any one of claims 1 to 11 and 371 to 378, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 355 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 358; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 359 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

361.

378. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 362, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

366.

379. 379. The monospecific antibody of any one of claims 1 to 11 and 378, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 362, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

366.

380. 379. The monospecific antibody of any one of claims 1 to 11, 378 and 379, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 362, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

366.

381. 381. The monospecific antibody of any one of claims 1 to 11 and 378 to 380, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 362, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

366.

382. 382. The monospecific antibody of any one of claims 1 to 11 and 378 to 381, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 362, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

366.

383. 382. The monospecific antibody of any one of claims 1 to 11 and 378 to 382, ​​comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 365, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

368.

384. 384. The monospecific antibody of any one of claims 1 to 11 and 378 to 383, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 362 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 365; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 366 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

368.

385. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 369, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

373.

386. 386. The monospecific antibody of any one of claims 1 to 11 and 385, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 369, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

373.

387. 387. The monospecific antibody of any one of claims 1 to 11, 385 and 386, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 369, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

373.

388. 388. The monospecific antibody of any one of claims 1 to 11 and 385 to 387, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 369, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

373.

389. 389. The monospecific antibody of any one of claims 1 to 11 and 385 to 388, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 369, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

373.

390. 389. The monospecific antibody of any one of claims 1 to 11 and 385 to 389, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 372, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

375.

391. 381. The monospecific antibody of any one of claims 1 to 11 and 385 to 380, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 369 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 372; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 373 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

375.

392. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 376, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

380.

393. 393. The monospecific antibody of any one of claims 1 to 11 and 392, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 376, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

380.

394. 394. The monospecific antibody of any one of claims 1 to 11, 392 and 393, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 376, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

380.

395. 395. The monospecific antibody of any one of claims 1 to 11 and 392 to 394, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 376, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

380.

396. 396. The monospecific antibody of any one of claims 1 to 11 and 392 to 395, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 376, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

380.

397. 397. The monospecific antibody of any one of claims 1 to 11 and 392 to 396, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 379, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

382.

398. 397. The monospecific antibody of any one of claims 1 to 11 and 392 to 397, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 376 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 379; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 380 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

382.

399. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 383, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

387.

400. 400. The monospecific antibody of any one of claims 1 to 11 and 399, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 383, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

387.

401. 401. The monospecific antibody of any one of claims 1 to 11, 399 and 400, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 383, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

387.

402. 402. The monospecific antibody of any one of claims 1 to 11 and 399 to 401, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 383, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

387.

403. 403. The monospecific antibody of any one of claims 1 to 11 and 399 to 402, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 383, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

387.

404. 404. The monospecific antibody of any one of claims 1 to 11 and 399 to 403, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 386, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

389.

405. 406. The monospecific antibody of any one of claims 1 to 11 and 399 to 404, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 383 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 386; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 387 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

389.

406. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 390, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

394.

407. 407. The monospecific antibody of any one of claims 1 to 11 and 406, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 390, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

394.

408. 408. The monospecific antibody of any one of claims 1 to 11, 406 and 407, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 390, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

394.

409. 409. The monospecific antibody of any one of claims 1 to 11 and 406 to 408, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 390, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

394.

410. 409. The monospecific antibody of any one of claims 1 to 11 and 406 to 409, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 390, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

394.

411. 411. The monospecific antibody of any one of claims 1 to 11 and 406 to 410, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 393, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

396.

412. 412. The monospecific antibody of any one of claims 1 to 11 and 406 to 411, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 390, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 393; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 394, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

396.

413. 413. The monospecific antibody of any one of claims 1 to 11 and 406 to 412, comprising a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 462, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 482, and a light chain (LC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:

472.

414. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 397, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

401.

415. 415. The monospecific antibody of any one of claims 1 to 11 and 414, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 397, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

401.

416. 416. The monospecific antibody of any one of claims 1 to 11, 414 and 415, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 397, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

401.

417. 417. The monospecific antibody of any one of claims 1 to 11 and 414 to 416, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 397, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

401.

418. 418. The monospecific antibody of any one of claims 1 to 11 and 414 to 417, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 397, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

401.

419. 419. The monospecific antibody of any one of claims 1 to 11 and 414 to 418, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 400, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

403.

420. 419. The monospecific antibody of any one of claims 1 to 11 and 414 to 419, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 397 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 400; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 401 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

403.

421. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 404, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

408.

422. 422. The monospecific antibody of any one of claims 1 to 11 and 421, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 404, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

408.

423. 423. The monospecific antibody of any one of claims 1 to 11, 421 and 422, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 404, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

408.

424. 424. The monospecific antibody of any one of claims 1 to 11 and 421 to 423, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 404, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

408.

425. 5. The monospecific antibody of any one of claims 1 to 11 and 421 to 424, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 404, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

408.

426. 426. The monospecific antibody of any one of claims 1 to 11 and 421 to 425, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 407, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 409, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

410.

427. 427. The monospecific antibody of any one of claims 1 to 11 and 421 to 426, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 404, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 407; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 408, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 409, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

410.

428. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 411, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

415.

429. 429. The monospecific antibody of any one of claims 1 to 11 and 428, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 411, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

415.

430. 429. The monospecific antibody of any one of claims 1 to 11, 428 and 428, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 411, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

415.

431. 431. The monospecific antibody of any one of claims 1 to 11 and 428 to 430, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 411, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

415.

432. 432. The monospecific antibody of any one of claims 1 to 11 and 428 to 431, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 411, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

415.

433. 432. The monospecific antibody of any one of claims 1 to 11 and 428 to 432, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 414, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 416, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

417.

434. 436. The monospecific antibody of any one of claims 1 to 11 and 428 to 433, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 411, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 414; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 415, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 416, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

417.

435. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 418, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

422.

436. 436. The monospecific antibody of any one of claims 1 to 11 and 435, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 418, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

422.

437. 437. The monospecific antibody of any one of claims 1 to 11, 435 and 436, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 418, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

422.

438. 438. The monospecific antibody of any one of claims 1 to 11 and 435 to 437, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 418, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

422.

439. 439. The monospecific antibody of any one of claims 1 to 11 and 435 to 438, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 418, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

422.

440. 440. The monospecific antibody of any one of claims 1 to 11 and 435 to 439, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 421, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

424.

441. 441. The monospecific antibody of any one of claims 1 to 11 and 435 to 440, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 418 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 421; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 422 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

424.

442. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 425, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

429.

443. 443. The monospecific antibody of any one of claims 1 to 11 and 442, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 425, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

429.

444. 444. The monospecific antibody of any one of claims 1 to 11, 442 and 443, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 425, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

429.

445. 445. The monospecific antibody of any one of claims 1 to 11 and 442 to 444, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 425, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

429.

446. 446. The monospecific antibody of any one of claims 1 to 11 and 442 to 445, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 425, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

429.

447. 447. The monospecific antibody of any one of claims 1 to 11 and 442 to 446, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 428, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

431.

448. 447. The monospecific antibody of any one of claims 1 to 11 and 442 to 447, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 425, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 428; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 429, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

431.

449. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 432, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

436.

450. 450. The monospecific antibody of any one of claims 1 to 11 and 449, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 432, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

436.

451. 451. The monospecific antibody of any one of claims 1 to 11, 449 and 450, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 432, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

436.

452. 452. The monospecific antibody of any one of claims 1 to 11 and 449 to 451, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 432, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

436.

453. 453. The monospecific antibody of any one of claims 1 to 11 and 449 to 452, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 432, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

436.

454. 454. The monospecific antibody of any one of claims 1 to 11 and 449 to 453, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 435, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

438.

455. 454. The monospecific antibody of any one of claims 1 to 11 and 449 to 454, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 432, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 435; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 436, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

438.

456. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 439, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

443.

457. 457. The monospecific antibody of any one of claims 1 to 11 and 456, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 439, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

443.

458. 458. The monospecific antibody of any one of claims 1 to 11, 456 and 457, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 439, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

443.

459. 100. The monospecific antibody of any one of claims 1 to 11 and 456 to 458, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 439, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

443.

460. 460. The monospecific antibody of any one of claims 1 to 11 and 456 to 459, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 439, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

443.

461. 460. The monospecific antibody of any one of claims 1 to 11 and 456 to 460, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 442, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

445.

462. 462. The monospecific antibody of any one of claims 1 to 11 and 456 to 461, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 439, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 442; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 443, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

445.

463. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 446, and a variable light (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

450.

464. 464. The monospecific antibody of any one of claims 1 to 11 and 463, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 446, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

450.

465. 5. The monospecific antibody of any one of claims 1 to 11, 463 and 464, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 446, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

450.

466. 466. The monospecific antibody of any one of claims 1 to 11 and 463 to 465, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 446, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

450.

467. 467. The monospecific antibody of any one of claims 1 to 11 and 463 to 466, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 446, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

450.

468. 468. The monospecific antibody of any one of claims 1 to 11 and 463 to 467, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 449, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

452.

469. 469. The monospecific antibody of any one of claims 1 to 11 and 463 to 468, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 446, and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 449; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 450, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

452.

470. 12. The monospecific antibody of any one of claims 1 to 11, comprising a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:

65.

471. 470. The monospecific antibody of any one of claims 1 to 11 and 470, comprising a variable heavy (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 61, and a variable light (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO:

65.

472. 65. The monospecific antibody of any one of claims 1 to 11, 470, and 470 to 471, comprising a variable heavy (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 61, and a variable light (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO:

65.

473. 473. The monospecific antibody of any one of claims 1 to 11 and 470 to 472, comprising a variable heavy (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 61, and a variable light (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO:

65.

474. 50. The monospecific antibody of any one of claims 1 to 11 and 470 to 473, comprising a variable heavy (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 61, and a variable light (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

65.

475. 50. The monospecific antibody of any one of claims 1 to 11 and 470 to 474, comprising a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

67.

476. 60. The monospecific antibody of any one of claims 1 to 11 and 470 to 475, comprising: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 61 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64; and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 65 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

67.

477. 50. The monospecific antibody of any one of claims 1 to 476, which binds to one or more amino acid residues of the VWF CK domain selected from D2726, R2730, K2735, E2744, D2746, K2757, D2763, and T2789.

478. The monospecific antibody of any one of claims 1 to 477, which binds to at least the following amino acid residues of the VWF CK domain: D2726, R2730, D2746, and K2757.

479. The monospecific antibody of any one of claims 1 to 477, which binds to at least the following amino acid residues of the VWF CK domain: R2730, K2735, E2744, and D2746.

480. The monospecific antibody of any one of claims 1 to 477, which binds to at least the following amino acid residues of the VWF CK domain: K2735, D2746, and K2757.

481. The monospecific antibody of any one of claims 1 to 477, which binds to at least the following amino acid residues of the VWF CK domain: R2730, D2746, and K2757.

482. The monospecific antibody of any one of claims 1 to 477, which binds to at least the following amino acid residues of the VWF CK domain: K2735, E2744, D2746, and D2763.

483. 50. The monospecific antibody of any one of claims 1 to 477, which binds to at least the following amino acid residues of the VWF CK domain: R2730, K2735, E2744, D2746, K2757, and D2763.

484. 478. The monospecific antibody of any one of claims 1 to 477, which binds to at least amino acid residue K2735 of the VWF CK domain.

485. The monospecific antibody of any one of claims 1 to 477, which binds to at least the following amino acid residues of the VWF CK domain: D2726, K2735, and K2757.

486. The monospecific antibody of any one of claims 1 to 477, which binds to at least the following amino acid residues of the VWF CK domain: K2735 and D2763.

487. The monospecific antibody of any one of claims 1 to 486, wherein binding of said monospecific antibody to said VWF protein does not result in alteration of the function of said VWF protein.

488. The monospecific antibody of any one of claims 1 to 487, wherein binding of said monospecific antibody to said VWF protein does not inhibit binding of said VWF protein to one or more binding partners.

489. 489. The monospecific antibody of claim 488, wherein the one or more binding partners are selected from the group consisting of Factor VIII, collagen, glycoprotein Ib (gp1b), glycoprotein IIb / IIIa (gpIIb / IIIa), and ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13 (ADAMTS13).

490. The monospecific antibody of any one of claims 487 to 489, wherein binding of said monospecific antibody to said VWF protein does not inhibit binding of said VWF protein to platelet cells.

491. 500. The monospecific antibody of any one of claims 1 to 490, wherein the accumulation of said VWF protein in plasma results in a plasma level of said VWF protein that is at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater compared to the plasma level of said VWF protein in the absence of said monospecific antibody.

492. the accumulation of said VWF protein in plasma is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 500%, 6000%, 6500%, 7000%, 7500%, 8000%, 8500%, 9000%, 9500%, 10000% or more.

493. 500. The monospecific antibody of any one of claims 1 to 492, wherein binding of said monospecific antibody to said VWF protein in plasma increases the plasma half-life of said VWF protein compared to the plasma half-life of said VWF protein in the absence of said monospecific antibody.

494. 494. The monospecific antibody of claim 493, wherein binding of said monospecific antibody to said VWF protein in plasma increases the plasma half-life of said VWF protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold or more compared to the plasma half-life of said VWF protein in the absence of said monospecific antibody.

495. The binding of the monospecific antibody to the VWF protein in plasma increases the plasma half-life of the VWF protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 900%, 1000%, 1100%, 1200%, 1300%, 1400%, 1500%, 1600%, 1700%, 1800%, 1900%, 2100%, 2200%, 2300%, 2400%, 2500%, 3000%, 3500%, 4000%, 4500%, 5000%, 5500%, 6000%, 6500%, 7000%, 7500%, 8000%, 9000%, 10000%, 11000%, 12000%, 13000%, 14000%, 15000%, 16000%, 17000%, 18000%, 19000%, 21000%, 22000%, 23000%, 24000%, 25000%, 30000%, 35000%, 40000%, 45000%, 5000%, 5500%, 6000%, 6500%, 7000%, 19000%, 21000%, 22000%, 23000%, 24000%, 2 494. The monospecific antibody of claim 493, wherein the antibody increases the expression level of the antibody by 50%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, or 10,000% or more.

496. 500. The monospecific antibody of any one of claims 1 to 495, wherein binding of said monospecific antibody to said VWF protein in plasma results in accumulation of Factor VIII (FVIII) protein in plasma compared to plasma levels of said FVIII protein in the absence of said monospecific antibody.

497. 497. The monospecific antibody of claim 496, wherein accumulation of said FVIII protein in plasma results in a plasma level of said Factor VIII protein that is at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater compared to the plasma level of said FVIII protein in the absence of said monospecific antibody.

498. the accumulation of the FVIII protein in plasma is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 497. The monospecific antibody of claim 496, which results in a plasma level of the FVIII protein that is 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000% or more.

499. 600. The monospecific antibody of any one of claims 1 to 598, wherein binding of said monospecific antibody to said VWF protein in plasma increases the plasma half-life of said FVIII protein compared to the plasma half-life of said FVIII protein in the absence of said monospecific antibody.

500. 500. The monospecific antibody of claim 499, wherein binding of said monospecific antibody to said VWF protein in plasma increases the plasma half-life of said FVIII protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold or more compared to the plasma half-life of said FVIII protein in the absence of said monospecific antibody.

501. The binding of the monospecific antibody to the VWF protein in plasma increases the plasma half-life of the FVIII protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, or 800% compared to the plasma half-life of the FVIII protein in the absence of the monospecific antibody. , 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, or 10,000% or more.

502. 502. The monospecific antibody of any one of claims 1 to 501, which specifically binds to a VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linkage in a 1:1 stoichiometry.

503. 502. The monospecific antibody of any one of claims 1 to 501, which specifically binds to a VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linkage in a 2:1 stoichiometry.

504. A dissociation constant (K) of less than 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 7 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.25 nM, 0.1 nM, 0.075 nM, 0.05 nM, 0.025 nM, 0.01 nM, or less ｄ 504. The monospecific antibody of any one of claims 1 to 503, which binds to the CK domain of the VWF protein via

505. 505. The monospecific antibody of any one of claims 1 to 504, which cross-reacts with VWF proteins of cynomolgus monkeys (Macaca fascicularis), house mice (Mus musculus) and / or dogs (Canis familiaris).

506. 506. The monospecific antibody of claim 505, which exhibits an affinity for the VWF protein of cynomolgus monkeys (Macaca fascicularis), house mice (Mus musculus) and / or dogs (Canis familiaris) that is up to 10-fold lower than the affinity of said monospecific antibody for human VWF protein.

507. The monospecific antibody of any one of claims 1 to 506, which is a human antibody, a humanized antibody, or a chimeric antibody.

508. The monospecific antibody of any one of claims 1 to 507, wherein the CK domain has the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:

6.

509. A complex comprising a VWF protein and a monospecific antibody according to any one of claims 1 to 508.

510. 509. A pharmaceutical composition comprising the monospecific antibody of any one of claims 1 to 508 and a pharmaceutically acceptable carrier, diluent, or excipient.

511. The pharmaceutical composition of claim 510, wherein the pharmaceutically acceptable carrier, diluent, or excipient is selected from the group consisting of stabilizers, buffers, surfactants, bulking agents, solvents, tonicity or osmolality adjusters, antioxidants, adjuvants, and antimicrobial agents.

512. 512. A method of treating a blood disorder characterized by excessive bleeding in a subject in need thereof, said method comprising administering to said subject a monospecific antibody according to any one of claims 1 to 508, or a pharmaceutical composition according to claim 510 or 511.

513. 513. The method of claim 512, wherein the blood disorder is selected from the group consisting of von Willebrand disease (VWD), Heydes syndrome, hemophilia A, platelet function disorders, and connective tissue disorders.

514. The method of claim 513, wherein the VWD is congenital VWD (cVWD) or acquired VWD (aVWD).

515. The method of claim 513 or 514, wherein the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

516. 516. The method of any one of claims 512-515, wherein said pharmaceutical composition treats one or more symptoms of said blood disorder selected from the group consisting of epistaxis, skin bleeding, bleeding from minor wounds, oral bleeding, angiodysplasia, gastrointestinal bleeding, bleeding from tooth extraction, postoperative bleeding, heavy menstrual bleeding, bleeding during childbirth, hematuria, muscle hematoma, joint bleeding, visceral bleeding, and central nervous system (CNS) bleeding.

517. The method of any one of claims 512 to 516, wherein the composition or pharmaceutical composition promotes platelet adhesion and / or aggregation in the subject.

518. 512. A method for accumulating VWF protein in the plasma of a subject in need thereof, comprising administering to said subject a composition comprising a monospecific antibody according to any one of claims 1 to 508, or a pharmaceutical composition according to claim 510 or 511.

519. 512. A method for accumulating FVIII protein in the plasma of a subject in need thereof, comprising administering to said subject a composition comprising a monospecific antibody according to any one of claims 1 to 508, or a pharmaceutical composition according to claim 510 or 511.

520. 512. A method for increasing the plasma half-life of a VWF protein in a subject in need thereof, comprising administering to said subject a composition comprising a monospecific antibody according to any one of claims 1 to 508, or a pharmaceutical composition according to claim 510 or 511.

521. 521. The method of any one of claims 512 to 520, wherein the composition is a pharmaceutical composition comprising said monospecific antibody and a pharmaceutically acceptable carrier, diluent, or excipient.

522. The method of claim 521, wherein the pharmaceutically acceptable carrier, diluent, or excipient is selected from the group consisting of stabilizers, buffers, surfactants, bulking agents, solvents, tonicity or osmotic pressure adjusters, antioxidants, adjuvants, and antimicrobial agents.

523. The method of any one of claims 512 to 522, wherein the composition or pharmaceutical composition is administered in combination with one or more additional therapeutic measures.

524. The method of claim 523, wherein the one or more additional therapeutic measures are selected from the group consisting of desmopressin (DDAVP), tranexamic acid (TXA), thalidomide, tamoxifen, ocreotide, a concentrate of plasma-derived VWF protein, a concentrate of VWF protein in a complex with FVIII protein, a concentrate of recombinant VWF protein, a concentrate of FVIII protein, hormone treatment, gene therapy, blood transfusion, platelet transfusion, surgery, and ablation.

525. The method of claim 524, wherein the gene therapy is FVIII gene therapy.

526. 526. The method of any one of claims 523-525, wherein the one or more additional therapeutic measures are administered to the subject before, simultaneously with, or after administration of the composition or pharmaceutical composition.

527. The method of any one of claims 512 to 526, wherein the subject is a human.

528. 527. A kit comprising a monospecific antibody according to any one of claims 1 to 508 or a pharmaceutical composition according to claim 510 or 511 and a package insert instructing a user of said kit to carry out the method according to any one of claims 512 to 527.

529. 512. A monospecific antibody according to any one of claims 1 to 508 or a pharmaceutical composition according to claim 510 or 511 for use as a medicament.

530. 530. The monospecific antibody or pharmaceutical composition of claim 529 for use in the treatment of a blood disorder characterized by excessive bleeding.

531. 512. A monospecific antibody according to any one of claims 1 to 508 or a pharmaceutical composition according to claim 510 or 511 for use in the treatment of a blood disorder characterised by excessive bleeding.

532. 532. The monospecific antibody or pharmaceutical composition for use according to claim 530 or 531, wherein said blood disorder characterized by excessive bleeding is selected from the group consisting of VWD, Heydes syndrome, hemophilia A, platelet function disorders, and connective tissue disorders.

533. The monospecific antibody or pharmaceutical composition for use according to claim 532, wherein the VWD is a cVWD or an aVWD.

534. 534. The monospecific antibody or pharmaceutical composition for use according to claim 532 or 533, wherein the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

Images